Fibrillin 2 gene knockdown inhibits invasion and migration of lung cancer cells.

Fibrillin 2 gene knockdown inhibits invasion and migration of lung cancer cells. Cell Mol Biol (Noisy-le-grand). 2020 Oct 31;66(7):190-196 Authors: Hong Q, Li R, Zhang Y, Gu K Abstract To investigate the effect of Fibrillin 2 (FBN2) expression on the invasion and migration of lung cancer cells, and the underlying mechanism. Protein and mRNA expressions of FBN2 were assayed. The relationship between FBN2 protein expression and clinical characteristics of lung cancer patients was analyzed. Correlation between FBN2 expression level and patient survival time was analyzed. Moreover, the mRNA and protein expression of FBN2 in lung cancer cells and human normal lung epithelial cells were assayed. After constructing low-expressing FBN2 cells, the cell proliferation, clone formation, migration and invasion capabilities were tested. Lung cancer cells proliferation with low FBN2 expression in nude mice was measured with a nude mouse tumorigenic experiment. The mRNA and protein expressions of FBN2 in lung cancer tissues were significantly higher than those in para-cancerous tissues (p<0.05).  FBN2 protein expression was significantly correlated with TNM stage, lymph node metastasis and histological type (p<0.05). Survival time was markedly reduced in patients with high FBN2 expression (p<0.001). The expressions of FBN2 mRNA and protein were markedly higher in lung cancer cells than in human normal lung epithelial cells. The proliferation, migration and ...
Source: Cellular and Molecular Biology - Category: Molecular Biology Tags: Cell Mol Biol (Noisy-le-grand) Source Type: research

Related Links:

Nutr Cancer. 2021 Aug 2:1-13. doi: 10.1080/01635581.2021.1957487. Online ahead of print.ABSTRACTLung cancer is a first leading cause of cancer related death worldwide. Quercetin (QUE) has chemo-preventive effect against a variety of cancers. However, the molecular mechanism of QUE mediated inhibition of cancer cell migration and epithelial to mesenchymal transition (EMT) is not clear in lung cancer. Therefore, this study investigates the effect of QUE on EMT and metastasis of lung cancer cell line (A549). The MTT assay, scratch wound healing assay, Transwell migration and invasion assay performed to assess the cell viabili...
Source: Nutrition and Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: OPN can be a metastasis-associated or specific biomarker for lung cancer and a potential target for antimetastatic treatment.PMID:34323425 | DOI:10.1002/ctm2.486
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
Lung squamous carcinoma (LUSC) is the second most frequent subtype of non-small cell lung cancer. Rarely gene alterations are identified in LUSC. Therefore, identifying LUSC-related genes to explain the relevant molecular mechanism is urgently needed. A potential biomarker, calcium-activated nucleotidase 1 (CANT1), was elevated in tissues of LUSC patients relative to normal cases based on the TCGA and/or GTEx database. CCK-8 and transwell tests were then implemented to measure the proliferative, invasive and migratory capacities, and showed that knockdown of CANT1 blocked LUSC cells proliferation. miR-607, predicted as an ...
Source: Anti-Cancer Drugs - Category: Cancer & Oncology Tags: Original Studies Source Type: research
Pathol Res Pract. 2021 Jul 10;224:153551. doi: 10.1016/j.prp.2021.153551. Online ahead of print.ABSTRACTAlthough mutations of genes are crucial events in tumorigenesis and development, the association between gene mutations and lung cancer metastasis is still largely unknown. The goal of this study is to identify driver and novel genes associated with non-small cell lung cancer (NSCLC) metastasis. Candidate genes were identified using a novel comprehensive analysis, which was based on bioinformatics technology and meta-analysis. Firstly, EGFR, KRAS, ALK, TP53, BRAF and PIK3CA were identified as candidate driver genes. Furt...
Source: Cell Research - Category: Cytology Authors: Source Type: research
CONCLUSION: NRT cells induced by RNA mutanome vaccine exert a significant anti-tumour effect in mouse lung cancer, and adoptive NRT cell therapy might be considered a feasible, effective therapeutic approach for lung cancer.PMID:34291357 | DOI:10.1007/s00432-021-03735-y
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Overall our data provide a new perspective on the pro-tumorigenic role of circulating EVs in high risk smokers and highlight the significance of miR-320-EVs as a new prognostic biomarker in lung cancer patients.PMID:34289890 | DOI:10.1186/s13046-021-02040-3
Source: Cell Research - Category: Cytology Authors: Source Type: research
CONCLUSION: NRT cells induced by RNA mutanome vaccine exert a significant anti-tumour effect in mouse lung cancer, and adoptive NRT cell therapy might be considered a feasible, effective therapeutic approach for lung cancer.PMID:34291357 | DOI:10.1007/s00432-021-03735-y
Source: Clinical Genitourinary Cancer - Category: Cancer & Oncology Authors: Source Type: research
CONCLUSION: Overall our data provide a new perspective on the pro-tumorigenic role of circulating EVs in high risk smokers and highlight the significance of miR-320-EVs as a new prognostic biomarker in lung cancer patients.PMID:34289890 | DOI:10.1186/s13046-021-02040-3
Source: Clinical Lung Cancer - Category: Cancer & Oncology Authors: Source Type: research
AbstractAmivantamab (amivantamab-vmjw; Rybrevant ™), a bispecific monoclonal antibody targeting epidermal growth factor receptor (EGFR) and mesenchymal epithelial transition factor (MET), is being developed by Janssen Biotech for the treatment of non-small cell lung cancer (NSCLC). On 21 May 2021, amivantamab received its first approval in the U SA for the treatment of adult patients with locally advanced or metastatic NSCLC harbouring EGFR Exon 20 insertion mutations whose disease has progressed on or after platinum-based chemotherapy. Amivantamab is in preregistration for NSCLC in the EU, Australia, Japan, Canada, ...
Source: Drugs - Category: Drugs & Pharmacology Source Type: research
.
Source: Cell Cycle - Category: Cytology Authors: Source Type: research
More News: Biology | Cancer | Cancer & Oncology | Epithelial Cancer | Genetics | Lung Cancer | Molecular Biology